![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancin... Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). Show more
BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.11 | -0.487588652482 | 22.56 | 23.475 | 20.63 | 184602 | 22.13994342 | CS |
4 | -0.25 | -1.1013215859 | 22.7 | 23.64 | 19.88 | 261058 | 21.81030423 | CS |
12 | 2.87 | 14.657814096 | 19.58 | 25.155 | 15.96 | 301706 | 21.36046992 | CS |
26 | 9.63 | 75.1170046802 | 12.82 | 26 | 10.9001 | 258622 | 20.02265833 | CS |
52 | 4.78 | 27.051499717 | 17.67 | 26 | 9.8 | 186290 | 18.10613074 | CS |
156 | -1.75 | -7.23140495868 | 24.2 | 26 | 9.8 | 190267 | 18.87450087 | CS |
260 | -1.75 | -7.23140495868 | 24.2 | 26 | 9.8 | 190267 | 18.87450087 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions